Semaglutide Benefits
Written by Alejandro Reyes
Founder & Lead Researcher
Reviewed by Peptide Nerds Editorial · Updated April 2026
How Semaglutide works
Semaglutide is a modified human GLP-1 analog with 94% structural similarity to native GLP-1. It binds to and activates the GLP-1 receptor (GLP-1R), triggering multiple downstream effects. In the hypothalamus, it activates POMC/CART neurons (satiety signals) and inhibits NPY/AgRP neurons (hunger signals), producing significant appetite reduction. In the gastrointestinal tract, it slows gastric emptying by 10-30%, promoting earlier satiety after meals. In the pancreas, it enhances glucose-dependent insulin secretion and suppresses glucagon release, improving blood sugar control. The molecule includes a C18 fatty acid chain that enables albumin binding, extending its half-life to approximately 7 days — allowing once-weekly dosing. Unlike native GLP-1, which is degraded by DPP-4 enzymes within minutes, semaglutide resists enzymatic breakdown through specific amino acid substitutions at positions 8 and 34.
Reported benefits
Based on published clinical trials, Semaglutide has been associated with the following benefits:
- Average 14.9% body weight loss over 68 weeks in the STEP 1 trial (n=1,961)
- One-third of participants lost 20%+ body weight (STEP 1)
- Sustained 15.2% weight loss at 2 years with continued treatment (STEP 5)
- Reduced appetite and food cravings through central nervous system action
- 20% reduction in major adverse cardiovascular events (SELECT trial, n=17,604)
- Improved HbA1c by 1.5-1.8% in patients with type 2 diabetes
- Reduced waist circumference by an average of 13.5 cm (STEP 1)
- Improved blood pressure, lipid profiles, and inflammatory markers
- Oral formulation available — Rybelsus (diabetes) and oral Wegovy (weight management)
- Well-established safety profile across 10,000+ trial participants
Supporting research
Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1)
New England Journal of Medicine, 2021 · PMID: 33567185
Participants (n=1,961) lost an average of 14.9% of body weight over 68 weeks compared to 2.4% with placebo. One-third of participants lost more than 20% of their body weight. GI side effects were the most common reason for discontinuation (7%).
Two-Year Effects of Semaglutide in Adults with Overweight or Obesity (STEP 5)
Nature Medicine, 2022 · PMID: 35132148
Sustained weight loss of 15.2% at 104 weeks with continued treatment, demonstrating long-term efficacy. Participants who switched to placebo at week 68 regained two-thirds of lost weight by week 120.
Semaglutide and Cardiovascular Outcomes in Patients with Overweight or Obesity (SELECT)
New England Journal of Medicine, 2023 · PMID: 37952131
In 17,604 adults with overweight/obesity and established cardiovascular disease, semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% compared to placebo over a mean follow-up of 33 months.
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo (STEP 4)
JAMA, 2021 · PMID: 33755728
After 20 weeks of semaglutide run-in, participants who continued treatment lost an additional 7.9% body weight by week 68, while those switched to placebo regained 6.9% — demonstrating the need for continued therapy.
Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes (STEP 2)
Lancet, 2021 · PMID: 33667417
In patients with type 2 diabetes (harder population to treat), semaglutide 2.4 mg produced 9.6% weight loss at 68 weeks compared to 3.4% with placebo, plus significant HbA1c improvement.
Semaglutide Once Weekly in Adolescents with Obesity (STEP TEENS)
New England Journal of Medicine, 2022 · PMID: 36563559
In adolescents aged 12-17, semaglutide 2.4 mg produced a 16.1% reduction in BMI at 68 weeks compared to 0.6% increase with placebo. Led to FDA approval for adolescent obesity.
Once-Weekly Semaglutide in Adults with Overweight and Cardiovascular Comorbidities (STEP 3)
JAMA, 2021 · PMID: 33625476
Combined with intensive behavioral therapy, semaglutide produced 16% weight loss at 68 weeks compared to 5.7% with intensive therapy plus placebo.
Important context
Benefits reported in clinical trials represent average outcomes across study populations. Individual results vary based on genetics, dosage, duration, and lifestyle factors.
Related peptides
Free Peptide Weight Loss Guide
Semaglutide vs. tirzepatide vs. retatrutide. Dosing protocols, side effects, gray market sourcing, and what the clinical trials found.